NovaBay Pharmaceuticals, Inc. (AMEX:NBY) shares are trading higher after the company announced it reached a definitive agreement to sell its Avenova assets for $9.5 million to Physician Recommended Nutraceuticals.
The Details: The company expects the transaction to close during the 2024 fourth quarter, pending NovaBay shareholder approval.
“I believe we have found an ideal home for Avenova. We expect the brand to continue to grow and flourish under PRN’s capable leadership and their ability to promote Avenova through their existing network of more than 5,000 eyecare professionals,” said NovaBay CEO Justin Hall.
“It’s gratifying to share that more people are using Avenova than ever before and with the support, resources and synergies that PRN can provide, we expect that number to continue to grow.”
How To Buy NovaBay Shares
By now you're likely curious about how to participate in the market for NovaBay Pharmaceuticals (AMEX:NBY) – be it to purchase shares, or even attempt to bet against the company.
Related Link: Legal Medical Cannabis Could Save US Healthcare $29B Annually, New Study Finds
NBY Price Action: At the time of writing, NovaBay stock is trading 25.0% higher at 62 cents per data from Benzinga Pro.
Image: Photo by roberto-sorin for Unsplash
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
